Jul 9 2013
NextBio, whose Big Data technology enables users to apply genomic data from disparate sources in novel and useful ways across life sciences research, today announced that Boehringer Ingelheim has signed a multi-year renewal agreement to the NextBio Research Platform. The new agreement also expands the user base for NextBio across Boehringer Ingelheim's global research organization.
"Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies and has been a user of NextBio Research for the past year," said Saeid Akhtari, NextBio President and Chief Executive Officer. "This expanded license and broadened access to the NextBio Research platform is a strong endorsement of our technology's value for enabling life scientists to quickly examine and understand their data in the context of published research worldwide.
"NextBio Research provides a comprehensive platform for exploratory, preclinical and early translational research in drug discovery and biotechnology research," Mr. Akhtari added. "Integrating proprietary analysis results with extensive curated content, NextBio enhances researchers' ability to design experiments, test hypotheses and validate results, leading to better target analysis, understanding of disease mechanisms, and analysis of results across species."
How cohesin mechanics and nanotracker tech are redefining DNA research